Danish pharmaceutical giant Novo Nordisk has confirmed a cyberattack that resulted in unauthorized access to limited non-public information, including sensitive patient health data from clinical trials and potentially high-value proprietary AI assets. The company, globally recognized for its blockbuster GLP-1 drugs Ozempic and Wegovy, identified the breach on June 11–12, 2026, following unauthorized access to […]
The post Novo Nordisk Confirms Cyberattack Exposing Patient Data and AI Assets appeared first on Cyber Security News.